Roche Veteran Launches Biotech Aiming To Disrupt Eye Drug Market
EyeBio Raises $65m In Series A
Executive Summary
Two veterans of the ophthalmology field are reuniting to launch a portfolio-based biotech company EyeBio.
You may also be interested in...
Phase II Data May Be Good Sign For 8mg Aflibercept, But Will Payers Bite?
There are concerns that even with better efficacy and dosing versus Eylea and biosimilars, payers may impose step-edits on Regeneron’s new high-dose version.
Could Faricimab Data Help Roche Maintain Ophthalmic Market Foothold?
The company published data for the bispecific antibody in wet AMD and DME, with non-inferior efficacy to Eylea and growing support for less frequent administration.
Safety Could Differentiate Nkarta’s CAR-NK Cell Therapy
Nkarta has updated its early results for its natural killer cell therapy, where it has shown promising efficacy and potentially superior safety to existing CAR-Ts.